CD274 and neoplasm: Given the BRAFV600E mutation and high PD-L1 expression, and with the goals of rapid tumor control and durable response, we initiated dabrafenib (150 mg twice daily), trametinib (2 mg once daily), and pembrolizumab (200 mg every three weeks) concurrently.